Eli Lilly and Company reported third quarter results ... the approval of Jaypirca in Japan for people with relapsed or refractory mantle cell lymphoma who are resistant or intolerant to other ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Sales have been limited but a recent approval in Japan could make it a significant growth driver in the quarters ahead. Despite falling on Wednesday, Eli Lilly stock is up by about 44% in 2024 as ...

Eli Lilly reported weaker results for the latest quarter than analysts ... In stock markets abroad, indexes were mostly lower ...

Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings ... The approval of Kisunla in Japan and Great Britain for the treatment of early symptomatic Alzheimer's disease.

U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent ...

Eli Lilly reported weaker results for the latest ... indexes were mostly lower in Europe and Asia despite a 1% rise for Japan’s Nikkei 225 as the Bank of Japan began a two-day policy meeting.